UNSPSC 51152101: Chlordiazepoxide/methscopolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA802. This VA Drug Class (GA802) classifies this compound as belonging to the group ANTIMUSCARINIC/ANTIPASMODIC COMBINATIONS.

UNSPSC 51152101 Chlordiazepoxide/methscopolamine is a Commodity code that nominally describes a specific pharmaceutical combination product, but the recent state and local opportunities tagged under it show minimal alignment with the code's scope. The Seminole County, Florida solicitation (IFB 60459723LAS) seeks naloxone and drug deactivation systems for community health initiatives—products unrelated to chlordiazepoxide/methscopolamine—while the Texas Health and Human Services Commission RFI (HHS0017013) addresses direct-to-manufacturer pharmacy benefit procurement strategy at the state level, a contracting mechanism rather than a specific pharmaceutical product line. The code shows little relevant recent activity in state and local procurement for the drug combination it names.

Geographic activity appears limited to Florida and Texas based on the two posted opportunities. Seminole County posted an IFB with a response deadline of July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with a two-year initial term and one-year renewal option; Texas HHS issued an RFI on April 3, 2026, to gather vendor capabilities for implementing a direct-to-manufacturer pharmacy program but did not solicit the specific drug product. No other jurisdictions or issuing bodies have posted opportunities under this code in the recent record. The mismatch between the code's pharmaceutical specificity and the actual solicitation scope suggests either tagging error or that state and local procurement under this code does not follow the UNSPSC definition closely.